Health News Releases

  • Today July 1
June 29, 14:10
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD001
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction ass
Groups Representing Patients, Healthcare Professionals and Pharmaceutical Industry Author New Principle on Use of AI In Healthcare
June 27, 14:20
Groups Representing Patients, Healthcare Professionals and Pharmaceutical Industry Author New Principle on Use of AI In Healthcare
Six leading international organizations representing patients, physicians, pharmacists, nurses, hospitals, and the pharmaceutical industry have today adopted the first joint ethical principle in the h
June 27, 13:45
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
In a significant showcase for investors, BeOne Medicines Ltd. (https://beonemedicines.com/) (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its
IFF’s 2024 Do More Good Report Highlights Progress in Sustainability and Innovation
June 27, 11:20
IFF’s 2024 Do More Good Report Highlights Progress in Sustainability and Innovation
IFF (https://www.iff.com/) (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health, and biosciences—has released its 2024 Do More Good Report (https://www.iff.com/sustainabilityre
BARRICURE at Immunodermatology Updates 2025
June 27, 10:20
MEDIPEAU Inc Showcases “BARRICURE” Medical Device Brand for Damaged Skin at Malaysia’s ‘Immunodermatology Updates 2025’ Symposium
On June 23, 2025, the ‘Immunodermatology Updates 2025’ symposium was held in Malaysia. At this event, CHAYA AND LIGHT SDN. BHD., the official Malaysian distribution partner of MEDIPEAU Inc., introduce
June 26, 11:00
Parse Biosciences GigaLab to Support Mount Sinai Researchers in Generating One of the Largest Alzheimer’s and Parkinson’s Single Cell Datasets
Parse Biosciences today announced their commitment to support researchers from the Icahn School of Medicine at Mount Sinai in generating one of the largest single cell datasets focused on understandin
June 25, 16:20
Takeda Announces New Assignments of Directors
Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meeting of Shareholders, held in Osaka today. Taked
June 25, 15:00
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients li
June 24, 16:20
Fujirebio Acquires Plasma Services Group and Strengthens Its Position as Provider of Critical and High Quality Biological Raw Materials to the IVD and Life Science Industries
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio, has acquired
June 24, 13:30
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges
As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper exa
Dr. Vishwanath Karad MIT World Peace University will welcome global thought leaders for the inaugura
June 19, 15:00
India to Host Inaugural World Technology Summit in 2025
World Technology (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.worldtechnology.games&esheet=54277017&newsitemid=20250616197549&lan=en-US&anchor=World+Technology&index=1&md5=b2
June 19, 14:00
SAIF Partners Files Definitive Proxy Materials in Connection with Sinovac Biotech 2025 Special Meeting of Shareholders; Nominates Ten Highly Qualified Director Candidates to the Board
SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15% of the outstanding common shares, toda
June 19, 10:15
LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials
Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay.
June 19, 08:42
SINOVAC Announces New Board Member
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang
Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)
June 18, 17:50
Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)
Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive supranuclea
June 18, 09:40
Celltrio Secures $15 Million Financial Investment to Accelerate Global Expansion in Cell Culturing and Cell & Gene Therapy Automation
Celltrio®, a pioneering life sciences company delivering advanced automation solutions for cell culturing and cell & gene therapy, today announced the closing of a $15 million financial investment rou
June 17, 16:35
Ecolab Life Sciences Launches New Bioprocessing Purification Resin to Drive Manufacturing Productivity
Ecolab Life Sciences today announced it has launched an innovative new resin to help achieve cost savings and optimize operations throughout the antibody manufacturing process. Purolite™ AP+50 is an a
June 15, 15:10
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on und
June 15, 14:10
HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
HOYA Vision Care (https://www.hoyavision.com/) today announced (https://www.hoyavision.com/about-hoya/hoya-vision-care-news/news/hoya-vision-care-unveils-updates-from-the-association-for-research-in-v
Masimo SedLine® Brain Function Monitoring
June 13, 11:50
New Study Finds Masimo SedLine® Brain Function Monitoring Offers Significant Advantages During Pediatric Anesthesia
Masimo (https://www.masimo.com/) (NASDAQ: MASI) today announced the findings of a randomized clinical trial published in JAMA Pediatrics in which Dr. Yasuko Nagasaka and colleagues at Tokyo Women’s Me
Professor Lee Hae-young during the ESH 2025 symposium in Milan, Italy (Photo: Sky Labs)
June 13, 10:40
Sky Labs Pioneers Future of Cuffless Blood Pressure Monitoring
Sky Labs (https://www.skylabs.io/en), a South Korean digital healthcare startup, captured global attention at the European Society of Hypertension (https://www.eshonline.org/) (ESH) 2025 in Milan, Ita
June 13, 08:53
Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025
Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW stud
June 13, 08:43
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U
Novotech, a global (CRO) and scientific advisory company, is featured in The Next Frontier, a global
June 11, 15:00
Novotech Showcased in Global Biotech Series for Innovation in Hepatitis B Research
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is featured in The Next Frontier, a global branded series presented by the Biotechnol
June 11, 12:05
HistoSonics and Cambridge University Unveil Europe’s First Edison™ Histotripsy System Powered by Li Ka Shing Foundation Gift
HistoSonics (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.histosonics.com&esheet=54271355&newsitemid=20250610200010&lan=en-US&anchor=HistoSonics&index=1&md5=090d8ce66da7672c352
June 11, 09:43
Medisca Secures Settlement With FlackTek, Reinforcing Patent Strength of MAZ® Mixer
Medisca and FlackTek have reached a settlement to resolve their patent dispute relating to the Medisca MAZ® mixer and related mixing technologies set forth in Medisca U.S. patent numbers 10,420,705, 1
June 11, 09:02
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U
June 10, 14:10
China’s Center for Drug Evaluation Accepts Merck’s Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
Merck, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company’
June 10, 09:50
Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research
Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the field of
Samsung Bioepis (President and CEO: Kyung-Ah Kim) has entered into a license, development and commer
June 09, 11:44
Samsung Bioepis Enters into a Strategic Partnership with NIPRO for Commercialization of Multiple Biosimilars in Japan
Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced today that the company has entered into a license, development and commercialization agreement with NIPRO Corporation (“NIPRO”) for multiple bio
Edison Histotripsy System Procedure for Kidney Tumor Animation
June 08, 13:10
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors
HistoSonics, Inc (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhistosonics.com%2F&esheet=54268467&newsitemid=20250606659747&lan=en-US&anchor=HistoSonics%2C+Inc&index=1&md5=9dd499a
June 08, 11:35
RAD 2025: Long-Term Data on Nemluvio® (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to Two Years
Galderma (SIX: GALD) today announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficacy of Nemluvio in moderate-to-severe atopic dermatitis.
June 08, 11:20
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™ fully human antibody mouse platform has been gra
Dr. Benjamin Chien founder and CEO of QPS Holdings, LLC.
June 08, 10:50
QPS Celebrates 30th Anniversary
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in 2025. Founded by Dr. Benjamin Chie
June 05, 17:20
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) appl
June 05, 17:10
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLE
June 05, 16:00
Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTTQ”) announced that NTB003 (formerly BCG009), a co-developed inj
June 05, 15:35
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidi
June 05, 13:35
Fundhost Selects SS&C to Power Fund Accounting & Registry Services
SS&C Technologies Holdings, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ssctech.com%2F%3Futm_campaign%3DSSC2025-Enterprise-Press-Release-0625%26utm_medium%3Dpressreleas
Louis Denis, MD, Chief Medical Officer, Byondis
June 04, 15:15
Byondis Announces First Patient Dosed in Phase 1 Clinical Trial of Novel SIRPα-Directed Monoclonal Antibody BYON4228 in Patients With Advanced or Metastatic Solid Tumors
Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the first patient dosed in its Phase 1 dose escalation
June 04, 11:40
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.takeda.com%2F&esheet=54264219&newsitemid=20250603992751&lan=en-US&anchor=Takeda&index=1&md5=06ff112e45cab46a48bacf2cabee3e8
June 04, 10:40
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54263182&newsitemid=20250602546858&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
June 03, 10:00
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54262852&newsitemid=20250531886517&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
June 02, 11:25
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.protagonist-inc.com%2F&esheet=54262872&newsitemid=20250531031305&lan=
HistoSonics Non-Invasive Edison Histotripsy System
June 01, 10:30
HistoSonics’ Edison Histotripsy System Gains Great Britain Early Market Access Under Unmet Clinical Needs Authorisation
HistoSonics (https://histosonics.com/), announced today that its Edison Histotripsy System for the non-invasive destruction of liver tumours has been granted controlled early limited market access in
May 30, 10:40
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection
Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has designated the HADLIMA™ (adalimumab-bwwd) high- and low-concentration (40 mg/
Exterior view of the New Building, Yamanashi Plant
May 29, 15:35
Rigaku Completes New Building at Yamanashi Plant
Rigaku Corporation, a global solution partner in X-ray analytical technologies and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; herei
BeOne Medicines' biologics manufacturing facility and clinical R&D center in Hopewell, NJ.
May 29, 15:30
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
BeOne Medicines Ltd. (https://beonemedicines.com/) (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company formerly known as BeiGene, Ltd., today announced its new name and redomiciliation
May 29, 09:14
Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor
Merck, a leading science and technology company, today announced the presentation of detailed positive results from Part 1 of the global Phase 3 MANEUVER trial evaluating pimicotinib, a potentially be
Nurse Naomi Oyoe Ohene Oti from Ghana – Winner of Aster Guardians Global Nursing Award 2025 (Photo:
May 28, 16:50
Ghana’s Naomi Oyoe Ohene Oti Wins Aster Guardians Global Nursing Award 2025 Worth USD 250,000
Nurse Naomi Ohene Oti from Ghana has been named the winner of the Aster Guardians Global Nursing Award 2025, selected from 100,000 applications from 199 countries. An Oncology Nurse Specialist and Hea
25 per page50 per page75 per page100 per page